Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity

Hu,Min; Wang,Dile; He,Tao

doi:10.3892/etm.2019.7472

Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity

Authors:
- Min Hu
- Dile Wang
- Tao He
View Affiliations

Affiliations: Department of Vascular Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: April 8, 2019 https://doi.org/10.3892/etm.2019.7472
Pages: 4427-4434
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study compared the efficacy and long‑term survival rate of trimetazidine and cilostazol in the treatment of lower extremity arteriosclerosis obliterans (ASO). A retrospectively analysis on the medical records of 206 patients with ASO who were admitted to The Central Hospital of Wuhan from January 2011 to May 2013 was performed, including 94 patients treated with trimetazidine (group A) and 112 patients treated with cilostazol (group B). On the basis of the same basic treatment, both groups were applied with these two drugs after two courses of treatments. Then the efficacy of clinical treatment, dorsal artery blood flow, anterior femoral artery, posterior tibial artery blood flow, brachial artery index, toe‑brachial index, painless walking distance, maximum walking distance, adverse reactions, 5‑year survival rates were compared. The total effective rate of clinical efficacy in group B was higher than group A (P<0.05). After the first course of treatment, the above indicators increased in both groups (P<0.05). After the end of the second course of treatment, the above‑mentioned index values in both groups were significantly increased (P<0.05). The improvement of the above indicators in group B were better than the trimetazidine group in both the first and second treatment courses (P<0.05). In group A, there were 15 cases of patients with lethargy and hypodynamia and 9 cases of dizziness and headache. There were significant differences between the 7th and 3rd cases of patients when compared to group B (P<0.05). The 5‑year survival rate of group A was lower than group B (P<0.05). The clinical efficacy of cliostazol in the treatment of ASO had a good effect, and there was only a few adverse reactions and the long‑term survival rate was high. It is worthy of being promoted in clinical practice.

View Figures

View References

1	Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, Levato L, Giles FJ, Dombret H, Mirault T, et al: Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 27:1316–1321. 2013. View Article : Google Scholar : PubMed/NCBI
2	He XM, Zheng YQ, Liu SZ, Liu Y, He YZ and Zhou XY: Altered plasma microRNAs as novel biomarkers for arteriosclerosis obliterans. J Atheroscler Thromb. 23:196–206. 2016. View Article : Google Scholar : PubMed/NCBI
3	Suzuki J, Shimamura M, Suda H, Wakayama K, Kumagai H, Ikeda Y, Akazawa H, Isobe M, Komuro I and Morishita R: Current therapies and investigational drugs for peripheral arterial disease. Hypertens Res. 39:183–191. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhang J, He S, Wang X and Wang D: Effect of trimetazidine on heart rate variability in elderly patients with acute coronary syndrome. Pak J Med Sci. 32:75–78. 2016.PubMed/NCBI
5	Chang J, Im GJ, Chae SW, Lee SH, Kwon SY, Jung HH, Chung AY, Park HC and Choi J: Protective role of trimetazidine against neomycin-induced hair cell damage in zebrafish. Clin Exp Otorhinolaryngol. 6:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
6	Atilgan D, Parlaktas BS, Uluocak N, Erdemir F, Markoc F, Saylan O and Erkorkmaz U: The effects of trimetazidine and sildenafil on bilateral cavernosal nerve injury induced oxidative damage and cavernosal fibrosis in rats. ScientificWorldJournal. 2014:9703632014. View Article : Google Scholar : PubMed/NCBI
7	Aksoy F, Dogan R, Ozturan O, Eren SB, Veyseller B, Pektas A and Hüseyinbas Ö: Protective effect of trimetazidine on amikacin-induced ototoxicity in rats. Int J Pediatr Otorhinolaryngol. 78:663–669. 2014. View Article : Google Scholar : PubMed/NCBI
8	Stadnik M, Handzlik-Orlik G, Sarnecki K, Krysiak R and Okopień B: Clinical aspects of the use of trimetazidine in the prevention and treatment of myocardial diseases. Przegl Lek. 70:730–734. 2013.(In Polish). PubMed/NCBI
9	Rondina MT and Weyrich AS: Targeting phosphodiesterases in anti-platelet therapy. Handb Exp Pharmacol. 210:225–238. 2012. View Article : Google Scholar
10	Kohda N, Tani T, Nakayama S, Adachi T, Marukawa K, Ito R, Ishida K, Matsumoto Y and Kimura Y: Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 96:261–268. 1999. View Article : Google Scholar : PubMed/NCBI
11	Sakamoto T, Ohashi W, Tomita K, Hattori K, Matsuda N and Hattori Y: Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-κB from the Toll-like receptor signaling pathways. Int Immunopharmacol. 62:120–131. 2018. View Article : Google Scholar : PubMed/NCBI
12	Criqui MH and Aboyans V: Epidemiology of peripheral artery disease. Circ Res. 116:1509–1526. 2015. View Article : Google Scholar : PubMed/NCBI
13	Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, et al Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee, : Executive Summary: Heart disease and stroke statistics - 2016 update: A report from the American Heart Association. Circulation. 133:447–454. 2016. View Article : Google Scholar : PubMed/NCBI
14	Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, et al: Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 382:1329–1340. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lawall H, Huppert P, Espinola-Klein C and Rümenapf G: The diagnosis and treatment of peripheral arterial vascular disease. Dtsch Arztebl Int. 113:729–736. 2016.PubMed/NCBI
16	Chong PF, Garratt AM, Golledge J, Greenhalgh RM and Davies AH: The intermittent claudication questionnaire: A patient-assessed condition-specific health outcome measure. J Vasc Surg. 36:764–771; discussion 863–864. 2002. View Article : Google Scholar : PubMed/NCBI
17	Kurklinsky AK and Levy M: Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453–460. Vasc Med. 18:234–236. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chao TH, Chen IC, Lee CH, Chen JY, Tsai WC, Li YH, Tseng SY, Tsai LM and Tseng WK: Cilostazol enhances mobilization of circulating endothelial progenitor cells and improves endothelium-dependent function in patients at high risk of cardiovascular disease. Angiology. 67:638–646. 2016. View Article : Google Scholar : PubMed/NCBI
19	O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B and Soong CV: The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 49:1226–1234. 2009. View Article : Google Scholar : PubMed/NCBI
20	Thompson PD, Zimet R, Forbes WP and Zhang P: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 90:1314–1319. 2002. View Article : Google Scholar : PubMed/NCBI
21	Asal NJ and Wojciak KA: Effect of cilostazol in treating diabetes-associated microvascular complications. Endocrine. 56:240–244. 2017. View Article : Google Scholar : PubMed/NCBI
22	Syrkin AL, Artiukhina EG, Kanorskiĭ SG and Chuntyzheva MM: Antiischemic efficacy of trimetazidine in patients with intermittent claudication and effort angina. Kardiologiia. 43:49–52. 2003.(In Russian). PubMed/NCBI
23	Roset PN: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638). Br J Surg. 100:18382013. View Article : Google Scholar : PubMed/NCBI
24	No authors listed, . Correction to: 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 135:e791–e792. 2017.PubMed/NCBI
25	Pearce L, Ghosh J, Counsell A and Serracino-Inglott F: Cilostazol and peripheral arterial disease. Expert Opin Pharmacother. 9:2683–2690. 2008. View Article : Google Scholar : PubMed/NCBI